Cryoport, Inc. (NASDAQ:CYRX) Given Consensus Rating of “Hold” by Brokerages

Cryoport, Inc. (NASDAQ:CYRX) has been assigned a consensus recommendation of “Hold” from the eight ratings firms that are currently covering the firm, MarketBeat reports. Six investment analysts have rated the stock with a hold rating and two have issued a buy rating on the company. The average twelve-month price target among analysts that have issued ratings on the stock in the last year is $18.25.

Several brokerages have recently issued reports on CYRX. Stephens reaffirmed an “equal weight” rating and set a $17.00 price target on shares of Cryoport in a research note on Wednesday, March 13th. Jefferies Financial Group started coverage on Cryoport in a report on Thursday, April 4th. They issued a “buy” rating and a $21.00 price objective for the company. B. Riley lowered shares of Cryoport from a “buy” rating to a “neutral” rating and dropped their price objective for the company from $22.00 to $19.00 in a research report on Friday. UBS Group lifted their price objective on shares of Cryoport from $14.50 to $17.00 and gave the stock a “neutral” rating in a research note on Friday, March 15th. Finally, Needham & Company LLC cut their price target on shares of Cryoport from $19.00 to $18.00 and set a “buy” rating for the company in a report on Wednesday, March 13th.

Insider Buying and Selling

In related news, Director Ramkumar Mandalam sold 3,217 shares of the business’s stock in a transaction on Friday, March 15th. The shares were sold at an average price of $14.68, for a total value of $47,225.56. Following the transaction, the director now owns 43,187 shares in the company, valued at $633,985.16. The transaction was disclosed in a document filed with the SEC, which is available through this link. In other news, Director Ramkumar Mandalam sold 3,217 shares of the company’s stock in a transaction dated Friday, March 15th. The shares were sold at an average price of $14.68, for a total transaction of $47,225.56. Following the transaction, the director now owns 43,187 shares in the company, valued at $633,985.16. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Jerrell Shelton sold 3,723 shares of the stock in a transaction on Monday, March 11th. The stock was sold at an average price of $16.35, for a total value of $60,871.05. Following the completion of the transaction, the chief executive officer now owns 636,951 shares in the company, valued at $10,414,148.85. The disclosure for this sale can be found here. Insiders sold a total of 73,940 shares of company stock valued at $1,147,538 in the last three months. Insiders own 10.10% of the company’s stock.

Hedge Funds Weigh In On Cryoport

Hedge funds and other institutional investors have recently modified their holdings of the business. Vanguard Group Inc. increased its holdings in Cryoport by 2.1% in the 3rd quarter. Vanguard Group Inc. now owns 3,559,092 shares of the company’s stock worth $48,795,000 after acquiring an additional 74,037 shares during the last quarter. Cadian Capital Management LP grew its stake in shares of Cryoport by 30.4% during the fourth quarter. Cadian Capital Management LP now owns 3,464,079 shares of the company’s stock valued at $53,659,000 after buying an additional 807,340 shares during the last quarter. Invesco Ltd. increased its stake in shares of Cryoport by 17.9% in the third quarter. Invesco Ltd. now owns 2,062,481 shares of the company’s stock worth $28,277,000 after buying an additional 313,853 shares during the period. Massachusetts Financial Services Co. MA increased its holdings in Cryoport by 46.9% during the 4th quarter. Massachusetts Financial Services Co. MA now owns 1,992,895 shares of the company’s stock valued at $30,870,000 after purchasing an additional 636,395 shares during the period. Finally, New York State Common Retirement Fund boosted its holdings in Cryoport by 29.9% in the fourth quarter. New York State Common Retirement Fund now owns 1,642,752 shares of the company’s stock valued at $25,446,000 after acquiring an additional 378,340 shares in the last quarter. Hedge funds and other institutional investors own 92.90% of the company’s stock.

Cryoport Trading Down 7.1 %

Cryoport stock opened at $15.95 on Friday. The business has a 50 day moving average price of $16.94 and a two-hundred day moving average price of $15.08. The stock has a market cap of $784.17 million, a price-to-earnings ratio of -7.25 and a beta of 1.60. Cryoport has a 12 month low of $9.00 and a 12 month high of $24.17. The company has a quick ratio of 11.16, a current ratio of 11.73 and a debt-to-equity ratio of 0.82.

Cryoport (NASDAQ:CYRX) last announced its earnings results on Tuesday, March 12th. The company reported ($0.51) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.19). The firm had revenue of $57.26 million for the quarter, compared to analyst estimates of $58.27 million. Cryoport had a negative return on equity of 11.86% and a negative net margin of 42.69%. As a group, equities analysts forecast that Cryoport will post -1.31 EPS for the current year.

Cryoport Company Profile

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.